Distinctive sensitivity of some T-leukemia cell lines to L-asparaginase.

Forty-two human hematopoietic cell lines were assessed for sensitivity to a four-day incubation with L-asparaginase. Eight of 13 T-leukemia cell lines and 1 of 7 non-T, non-B common acute lymphoblastic leukemia cell lines exhibited an ID50 (50% growth inhibition dose) of less than 0.0001 IU/ml. Seven of these sensitive cell lines were further cultured in L-asparagine-free medium and were found not to proliferate. Five T-leukemia cell lines, 6 non-T, non-B common acute lymphoblastic leukemia cell lines, 10 "abnormal" B-cell lines, 4 "normal" B-cell lines, 3 myeloma cell lines and 5 myeloid leukemia cell lines had ID50 values between 0.1 and 1.0 IU/ml. Twelve of these resistant cell lines were able to proliferate in L-asparagine-depleted medium. The results indicate that some patients with T-cell acute lymphoblastic leukemia might respond to this enzymatic antineoplastic drug, L-asparaginase, at low dose.

[1]  J. Brouet,et al.  Acute lymphoblastic leukemia with pre-B-cell characteristics. , 1979, Blood.

[2]  Richard Hurwitz,et al.  Characterization of a leukemic cell line of the pre‐B phenotype , 1979, International journal of cancer.

[3]  M. Greaves,et al.  A Philadelphia chromosome positive human leukaemia cell line (NALM-1) with pre-B characteristics. , 1979, Leukemia research.

[4]  W. A. Smithson,et al.  L-asparaginase used with cytosine arabinoside in treatment of childhood acute lymphocytic leukemia refractory to vincristine and prednisone. , 1979, Medical and pediatric oncology.

[5]  J. Brouet,et al.  The immunological classification of acute lymphoblastic leukemias , 1978, Cancer.

[6]  B. Drewinko,et al.  Establishment of a human plasma cell line in vitro. , 1978, Cancer research.

[7]  H. Koeffler,et al.  Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity. , 1978, Science.

[8]  M. Greaves,et al.  Expression of an antigen associated with acute lymphoblastic leukemia in human leukemia-lymphoma cell lines. , 1978, Journal of the National Cancer Institute.

[9]  M. Cooper,et al.  Pre-B-cell leukemia. A new phenotype of childhood lymphoblastic leukemia. , 1978, The New England journal of medicine.

[10]  S. Morikawa,et al.  Two E‐rosette‐forming lymphoid cell lines , 1978, International journal of cancer.

[11]  K. Starling,et al.  Use of L-asparaginase and cytosine arabinoside for refractory acute lymphocytic leukemia with particular reference to T-cell leukemia. , 1978, Medical and pediatric oncology.

[12]  S. Collins,et al.  Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture , 1977, Nature.

[13]  J. Minowada,et al.  L-asparagine requirements of human T-lymphocytes and B-lymphocytes in culture. , 1977, Journal of the National Cancer Institute.

[14]  J. Yodoi,et al.  Adult T-cell leukemia: clinical and hematologic features of 16 cases. , 1977, Blood.

[15]  M. Oshimura,et al.  Cytogenetic and immunoglobulin markers of human leukemic B-cell lines. , 1977, Cancer research.

[16]  I. Miyoshi,et al.  Human B cell, T cell and null cell leukaemic cell lines derived from acute lymphoblastic leukaemias , 1977, Nature.

[17]  M. Greaves,et al.  Phenotypic characterisation of a unique non-T, non-B acute lymphoblastic leukaemia cell line , 1977, Nature.

[18]  G. Bornkamm,et al.  Characterization of EBV‐genome negative “null” and “T” cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non‐Hodgkin lymphoma , 1977, International journal of cancer.

[19]  T. Lister,et al.  Antisera to acute lymphoblastic leukemia cells. , 1975, Clinical immunology and immunopathology.

[20]  B. Giovanella,et al.  An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. , 1975, Intervirology.

[21]  J. Colofiore,et al.  Asparagine-requiring tumor cell lines and their non-requiring variants: cytogenetics, biochemistry and population dynamics. , 1973, Genetics.

[22]  W. P. Summers,et al.  The rate of mutation of L5178Y asparagine-dependent mouse leukemia cells to asparagine independence and its biological consequences. , 1973, Cancer research.

[23]  C. Lozzio,et al.  Cytotoxicity of a factor isolated from human spleen. , 1973, Journal of the National Cancer Institute.

[24]  I. Fidler,et al.  Effects of L-asparaginase on lymphocyte surface and blastogenesis. , 1972, Cancer Research.

[25]  G. Moore,et al.  Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. , 1972, Journal of the National Cancer Institute.

[26]  G. Moore.  Cultured human lymphocytes , 1972, Journal of surgical oncology.

[27]  A. Sandberg,et al.  Chromosomal variability in ten cloned sublines of a newly established Burkitt's lymphoma cell line , 1971, Cancer.

[28]  J. Bertino,et al.  L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. , 1971, Annals of internal medicine.

[29]  J. Morrow.  Mutation rate from asparagine requirement to asparagine non‐requirement , 1971, Journal of Cellular Physiology.

[30]  J. Pontén,et al.  Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. , 1970, Clinical and experimental immunology.

[31]  H. Lazarus,et al.  The question of stemlines in human acute leukemia. Comparison of cells isolated in vitro and in vivo from a patient with acute lymphoblastic leukemia. , 1970, Experimental cell research.

[32]  D. Kessel,et al.  Inhibition of Glycoprotein Synthesis in L5178Y Mouse Leukaemic Cells by L-Asparaginase in vitro , 1970, Nature.

[33]  D. Karnofsky,et al.  Clinical results of treatment with E. coli L‐asparaginase in adults with leukemia, lymphoma, and solid tumors , 1970, Cancer.

[34]  George,et al.  Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. , 1968, Cancer research.

[35]  G. Klein,et al.  Studies of burkitt lymphoma cells. I. Establishment of a cell line (B35M) and its characteristics , 1967, Cancer.

[36]  G. Moore,et al.  Production of Free Light Chains of Immunoglobulin by a Hematopoietic Cell Line Derived from a Patient with Multiple Myeloma.∗ , 1967, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[37]  Y. Hinuma,et al.  Cloning of Immunoglobulin-Producing Human Leukemic and Lymphoma Cells in Long-Term Cultures.∗ , 1967, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[38]  L. Old,et al.  SUPPRESSION OF MURINE LEUKEMIAS BY L-ASPARAGINASE INCIDENCE OF SENSITIVITY AMONG LEUKEMIAS OF VARIOUS TYPES: COMPARATIVE INHIBITORY ACTIVITIES OF GUINEA PIG SERUM L-ASPARAGINASE AND ESCHERICHIA COLI L-ASPARAGINASE , 1967 .

[39]  H. Lazarus,et al.  Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia , 1965, Cancer.

[40]  R. Pulvertaft,et al.  CYTOLOGY OF BURKITT'S TUMOUR (AFRICAN LYMPHOMA). , 1964, Lancet.

[41]  J. Broome,et al.  EVIDENCE THAT THE L-ASPARAGINASE OF GUINEA PIG SERUM IS RESPONSIBLE FOR ITS ANTILYMPHOMA EFFECTS , 1963, The Journal of experimental medicine.

[42]  J. Broome.  Evidence that the L-Asparaginase Activity of Guinea Pig Serum is responsible for its Antilymphoma Effects , 1961, Nature.

[43]  G. A. Fischer,et al.  The requirement for L-asparagine of mouse leukemia cells L5178Y in culture. , 1961, Cancer research.

[44]  H. Eagle,et al.  Amino acid metabolism in mammalian cell cultures. , 1959, Science.

[45]  T. McCoy,et al.  The amino acid requirements of the Jensen sarcoma in vitro. , 1959, Cancer research.

[46]  R. E. Neuman,et al.  The amino acid requirements of the Walker carcinosarcoma 256 in vitro. , 1956, Cancer research.

[47]  J. G. Kidd.  REGRESSION OF TRANSPLANTED LYMPHOMAS INDUCED IN VIVO BY MEANS OF NORMAL GUINEA PIG SERUM , 1953, The Journal of experimental medicine.